In the current issue of the OncoWuXi Newsletter, we would like to share with you our updates on genetically engineered Ba/F3 cell lines and corresponding
in vivo/in vitro
validation data. Other interesting topics covered in this issue include our
efficacy platform for bispecific antibodies,
and CLDN18.2 targeted
OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi AppTec Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.